HTG Molecular Diagnostics, Inc. develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq EGFR, KRAS, and BRAF mutation assay; HTG EdgeSeq ALKPlus assay EU; and HTG EdgeSeq DLBCL cell of origin assay EU. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; master collaboration agreement with Merck KGaA; governing agreement with QIAGEN Manchester Limited; and development and professional services agreement with Invetech PTY Ltd. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Phone877-289-2615
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$14.76 million
Profitability
Miscellaneous
Employees98
OptionableOptionable
HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions
What is HTG Molecular Diagnostics' stock symbol?
HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."
How were HTG Molecular Diagnostics' earnings last quarter?
HTG Molecular Diagnostics Inc (NASDAQ:HTGM) issued its earnings results on Thursday, August, 9th. The medical research company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.05. The medical research company earned $4.91 million during the quarter, compared to the consensus estimate of $5.30 million. HTG Molecular Diagnostics had a negative return on equity of 83.42% and a negative net margin of 74.94%. View HTG Molecular Diagnostics' Earnings History.
When is HTG Molecular Diagnostics' next earnings date?
What price target have analysts set for HTGM?
5 equities research analysts have issued 12-month target prices for HTG Molecular Diagnostics' shares. Their predictions range from $7.00 to $8.00. On average, they anticipate HTG Molecular Diagnostics' share price to reach $7.50 in the next year. This suggests a possible upside of 219.1% from the stock's current price. View Analyst Price Targets for HTG Molecular Diagnostics.
What is the consensus analysts' recommendation for HTG Molecular Diagnostics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for HTG Molecular Diagnostics.
What are Wall Street analysts saying about HTG Molecular Diagnostics stock?
Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock:
- 1. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (1/15/2019)
- 2. Cantor Fitzgerald analysts commented, "We reaffirm our OW rating on HTGM. We think HTG’s EdgeSeq offers an attractive workflow solution that addresses key challenges in many existing molecular profiling technologies on the market. We view RNA-based panels as well-positioned to capitalize on trends in biomarker development, including faster turnaround time, lower sample-volume requirement, and next-gen sequencing (NGS)- based testing. We think shares of HTG will be rewarded with consistent product and service revenue acceleration along with a demonstrated growing pipeline of exclusive revenue-generating PDPs." (1/14/2019)
- 3. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $222M excluding debt. This includes a discounted cash flow analysis based asset value at $231M for the HTG EdgeSeq platform, with a 15% discount rate and 0% terminal growth rate." (12/19/2018)
Has HTG Molecular Diagnostics been receiving favorable news coverage?
Media coverage about HTGM stock has trended negative this week, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. HTG Molecular Diagnostics earned a coverage optimism score of -2.8 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of HTG Molecular Diagnostics' key competitors?
Who are HTG Molecular Diagnostics' key executives?
HTG Molecular Diagnostics' management team includes the folowing people:
- Mr. Timothy B. Johnson, CEO & Director (Age 58)
- Mr. John L. Lubniewski, Pres & COO (Age 55)
- Mr. Shaun D. McMeans, Sr. VP, CFO, Sec. & Treasurer (Age 57)
- Dr. Maureen T. Cronin, Sr. VP & Chief Scientific Officer (Age 66)
- Dr. Debra A. Gordon, Sr. VP and Chief Legal Counsel (Age 59)
When did HTG Molecular Diagnostics IPO?
(HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.
Who are HTG Molecular Diagnostics' major shareholders?
HTG Molecular Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Stonepine Capital Management LLC (9.39%), Acadian Asset Management LLC (0.80%), Geode Capital Management LLC (0.76%), Stifel Financial Corp (0.59%), Requisite Energy Fund I LP (0.35%) and BlackRock Inc. (0.31%). Company insiders that own HTG Molecular Diagnostics stock include Holdings A/S Novo, Plc Glaxosmithkline and Shaun D Mcmeans. View Institutional Ownership Trends for HTG Molecular Diagnostics.
Which major investors are selling HTG Molecular Diagnostics stock?
Which major investors are buying HTG Molecular Diagnostics stock?
HTGM stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Acadian Asset Management LLC, Requisite Energy Fund I LP, Millennium Management LLC, Geode Capital Management LLC, BlackRock Inc., Raymond James Financial Services Advisors Inc. and Jane Street Group LLC. View Insider Buying and Selling for HTG Molecular Diagnostics.
How do I buy shares of HTG Molecular Diagnostics?
Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is HTG Molecular Diagnostics' stock price today?
One share of HTGM stock can currently be purchased for approximately $2.35.
How big of a company is HTG Molecular Diagnostics?
HTG Molecular Diagnostics has a market capitalization of $66.98 million and generates $14.76 million in revenue each year. The medical research company earns $-18,960,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. HTG Molecular Diagnostics employs 98 workers across the globe.
What is HTG Molecular Diagnostics' official website?
How can I contact HTG Molecular Diagnostics?
HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.
MarketBeat Community Rating for HTG Molecular Diagnostics (NASDAQ HTGM)
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
